

# Double Materiality Assessment Report

# Executive Summary

In 2024 Hansa Biopharma conducted a Double Materiality Assessment (DMA) to align with the Corporate Sustainability Reporting Directive (CSRD) and European Sustainability Reporting Standards (ESRS). This process engaged key stakeholders to evaluate material topics based on both impact and financial relevance.

The assessment resulted in 10 prioritized material topics, with six identified as critical to Hansa’s sustainable operations and strategic goals. While climate change was not deemed highly material due to Hansa’s limited environmental footprint, the company remains committed to transparency in emissions reporting.

## Top 10 Topics

TOPICS & ESRS MAPPING	IMPACT MATERIALITY					FINANCIAL MATERIALITY				
	5	4	3	2	1	1	2	3	4	5
Product Quality & Safety (S4)										
Clinical Trial Safety & Ethics (S4/G1)										
Business Conduct, Ethics & Compliance (G1)										
Equitable Access to Healthcare (S2,S3)										
Supply Chain Managements (S2, G1)										
Employee Health, Safety & Wellbeing (S1)										
Data Privacy & Integrity (S4)										
Diversity & Inclusion (S1, G1)										
Carbon Footprint & Climate Change (E1)										
Circular Economy & Waster Management (E5)										

# About the Report


Hansa Biopharma is committed to developing innovative, life-saving treatments for patients with rare immunological conditions. As a pioneering biopharma company, Hansa prioritizes ethical conduct, patient-centric innovation, and sustainability across its operations.

The company conducted its last materiality assessment in 2021. In alignment with the commitment outlined in the 2023 Annual and Sustainability Reports, Hansa undertook a Double Materiality Assessment (DMA) in 2024 to refine its understanding of key sustainability topics and their impact on both stakeholders and the business.

This assessment was conducted in accordance with the Corporate Sustainability Reporting Directive (CSRD) and guided by the European Sustainability Reporting Standards (ESRS), ensuring alignment with evolving regulatory frameworks and industry best practices. The DMA evaluated both the company’s impact on stakeholders and the environment (impact materiality) and how external sustainability risks and opportunities influence Hansa's business (financial materiality).

By conducting the DMA in 2024, Hansa proactively positioned itself to meet the CSRD requirements for the 2026 reporting cycle. This approach reflects the company’s commitment to transparency, strategic foresight, and continuous improvement, ensuring that sustainability remains a core focus while preparing for full compliance with future reporting obligations.

## Double Materiality Assessment covers two aspects



**A double materiality assessment must cover both an entity’s own operations as well as its upstream and downstream value chain**

**Impact Materiality:** The impact the company has on people and the environment. Measured by Severity (Scale, Scope, Irremediable character) and Likelihood of occurrence.

**Financial Materiality:** The financial impact (Risk and Opportunity) on the company. Measured by Financial Severity and Likelihood of occurrence.]

# Steps in Conducting the DMA

## **1 STAKEHOLDER IDENTIFICATION & ENGAGEMENT**

Conducted stakeholder mapping and engaged key internal and external groups to identify material topics, gather insights, and align with CSRD requirements.

## **2 IDENTIFYING LONG LIST OF RELEVANT TOPICS**

Identified a comprehensive 'long list' of over 60 sustainability topics across 15 areas, in alignment with regulations, global frameworks like GRI and SASB, MSCI and industry best practices.

## **3 SHORTLISTING MATERIAL IMPACTS, RISKS AND OPPORTUNITIES**

Refined the long list of 60 topics through stakeholder feedback and assessment of impacts, risks, and opportunities to arrive at 10 key material topics critical to Hansa's strategy.

## **4 VALIDATING AND FINALIZING THE MATERIALITY MATRIX**

Finalized the Materiality Matrix by validating the 10 topics with the Executive Committee, prioritizing six key areas while ensuring critical oversight for the remaining four topics.

# Stakeholder Identification and Engagement

Hansa began the Double Materiality Assessment (DMA) with a comprehensive stakeholder mapping exercise, identifying key stakeholder groups based on their level of influence and interest. This process highlighted the critical stakeholder groups that play a pivotal role in shaping Hansa’s sustainability priorities and strategic direction.

For the DMA, Hansa engaged with these 10 stakeholder groups: Employees, Patient Advocacy Groups, Suppliers, Clinical Partners, Healthcare Providers, Financial Analysts, Board Members, Internal Experts, Payers, and Partners. Engagement methods included surveys, interviews, focus groups, and desktop research, involving over 50 participants.

Through proactive and engaging discussions, each stakeholder group provided invaluable and nuanced insights into Hansa’s impacts, risks, and opportunities (IRO), as well as its broader sustainability strategy moving forward. These collaborative exchanges not only identified key material topics but also refined Hansa’s focus areas, ensuring they are well-aligned with stakeholder expectations and the company’s long-term strategic goals.

Further details on the feedback and key themes from each stakeholder group are available in **appendix 1**.

Board Members (I)	Leadership Team (I,S)	HCPs (I)
Internal Experts (I)	Partners (I)	Payers (R)
Suppliers (I)	Partners (I)	Investors (I,R)

*I - Interview, S – Survey and R- Secondary Research*

## Identifying a Long List of relevant topics



As part of the Double Materiality Assessment journey, Hansa Biopharma identified a comprehensive long list of over 60 sustainability topics spanning 15 broad areas. This list was meticulously aligned with leading frameworks, including the European Sustainability Reporting Standards (ESRS), Datamaran, the Global

Reporting Initiative (GRI), MSCI Sustainalytics, and insights from industry leaders in biopharma. The topics were also tailored to reflect Hansa's unique operational priorities and strategic focus areas, ensuring the long list served as a robust foundation for the subsequent materiality assessment steps.

### **Shortlisting material impacts, risks and opportunities (IRO)**


The long list of over 60 sustainability topics was refined through a structured process that incorporated internal and external stakeholder feedback, alignment with Hansa's mission and strategic goals, and assessment of both impact materiality and financial materiality. Each topic was evaluated based on its actual and potential impacts, as well as associated risks and opportunities, using methodologies aligned with recognized sustainability standards. The resulting 10 key material topics not only address stakeholder concerns but also align with regulatory standards and Hansa's strategic objectives, ensuring a focused and actionable sustainability roadmap.

# Validating and Finalizing the Materiality Matrix

Once the 10 material topics were shortlisted, the Executive Committee convened to critically analyze and validate each topic. Through this process, the six most impactful and financially significant topics were prioritized and plotted in the Materiality Matrix, representing the key focus areas for Hansa’s sustainability strategy.

While the remaining four topics, including Diversity, Equity, and Inclusion (DEI) and Data Privacy and Integrity, were not among the top six, they remain critical to Hansa’s operations. These areas will continue to be monitored and addressed through robust measures such as the risk management framework. Hansa’s strong commitment to DEI ensures an inclusive and equitable workplace, while its emphasis on data privacy safeguards sensitive patient and organizational information.

On climate change, although assessed as non-material given Hansa’s small environmental footprint and limited operational scale, the company is committed to capturing and disclosing emissions data and other environmental metrics transparently. This approach allows Hansa to meet regulatory requirements while remaining vigilant about potential changes in its environmental impact.





[The following matrix visualizes the final 10 material topics by their relative impact on stakeholders (vertical axis) and financial relevance to Hansa (horizontal axis). The topics in the upper right quadrant are the six Executive Committee-prioritized areas, reflecting the topics that combine high impact with financial significance.]

# Looking ahead - Next Steps in Hansa's Sustainability Journey

Hansa Biopharma remains committed to advancing its sustainability efforts through continuous monitoring, stakeholder engagement, and strategic alignment. The identified material topics will guide the company's sustainability initiatives, risk management, and operational improvements, ensuring alignment with stakeholder expectations and regulatory standards.

Looking ahead, Hansa plans to:

- **Identify Gaps and Mitigate Risks:** Address any gaps in sustainability practices and implement effective risk management strategies.
- **Set and Monitor KPIs:** Develop measurable Key Performance Indicators (KPIs) for each material topic and track progress annually.
- **Strategic Alignment:** Collaborate with leadership to integrate sustainability into core business functions and decision-making processes.
- **Stakeholder Engagement:** Maintain ongoing dialogue with stakeholders to refine focus areas and address emerging priorities.
- **Sustainability Reporting:** Publish a comprehensive sustainability report for the 2026 reporting cycle, aligning with CSRD requirements and demonstrating progress and transparency.

# Appendix 1

## Stakeholder Feedback and Key themes

Stakeholder Group	Engagement Method	Key Topics Raised
Employees	Focus Groups, Surveys	Diversity and inclusion, hybrid work models, employee well-being, organizational culture, Sustainable Operations (e.g., biking initiatives, virtual meetings).
Patient Advocacy Groups	Interviews	Equitable access to healthcare, environmental impacts of dialysis, education on hypersensitization and transplant options, diversity in clinical trials and addressing disparities for underserved populations
Healthcare Professionals (HCPs)	Interviews	Clinical Trial Safety, Ethics and Transparency, Equity in Organ Allocation, and Advanced Use of Real-World Data. Data privacy, inclusivity in trials, and patient-centered protocols.
Suppliers	Surveys, Discussions	Cold chain logistics, Supply chain sustainability, ESG compliance, data privacy, and waste management in packaging.
Board Members	Interviews, discussions	Governance priorities, Green financing, setting realistic sustainability goals, and transparency in reporting.
Partners	Interviews	Reducing patient access barriers, Data privacy in trials, and Equity and Diversity in workforce and clinical settings.
Payers	Desktop Research	Patient access and affordability, Regulatory compliance, the role of technology in enhancing ESG strategies, supply chain resilience, and real-world evidence integration.

Internal Experts	Discussions/ interviews	Regulatory compliance, vendor oversight, and alignment with ESG practices. Cold chain management, Circular economy in packaging, and post-marketing surveillance.
Financial Analysts	Interviews, desktop research	Regulatory pressures, Risks in supply chain, equitable pricing/ pricing access balance, and ESG integration in financial decision-making and risks of reputational loss.
Clinical Partners	Interviews	Transparency in Trial Reporting, D&I in Trials, Use of Remote Monitoring, and Balance Between Safety and Speed in Development. Regulatory adherence, patient engagement, and operational efficiencies.